
Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU). CDDP (12-15 mg/m2) and 5-FU (300 mg/m2) were given on day 1-5 and ADM (30 mg/m2) was given on day 1. Courses were repeated every 3-4 weeks. In 4 cases of transitional cell carcinoma, 1 complete remission and 3 partial remissions, were obtained, but in 2 cases of adenocarcinoma, only symptomatic improvement was observed. General toxic effects consisted of vomiting, alopecia, myelosuppression and disturbance of renal function, but the therapy was well tolerated. Our encouraging results to date seemed to indicate the higher degree of effectiveness of this combination chemotherapy against the chemoresistant disease.
Male, Carcinoma, Transitional Cell, Urologic Neoplasms, Adenocarcinoma, Middle Aged, Doxorubicin, Humans, Drug Therapy, Combination, Female, Fluorouracil, Cisplatin, Neoplasm Metastasis, Aged
Male, Carcinoma, Transitional Cell, Urologic Neoplasms, Adenocarcinoma, Middle Aged, Doxorubicin, Humans, Drug Therapy, Combination, Female, Fluorouracil, Cisplatin, Neoplasm Metastasis, Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
